Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of EETs and NO in Raynaud's Hyperemia (REFRAIN)
NCT02183779Unknown
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2014
- Primary completion
- Oct 2016
- Countries
- 1
01
Overview
Trial (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Post-occlusive hyperemia amplitude at Day 1. Status: unknown.
Beyond the preview
Go deeper on NCT02183779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183779.